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Abstract 
Development of peptide-based conjugates for targeted tumour therapy is a current research 
topic providing new possibilities in cancer treatment. In this study, VHLGYAT heptapeptide 
selected by phage display technique for HT-29 human colon cancer was investigated as 
homing peptide for drug delivery. Daunomycin was conjugated to the N-terminus of the 
peptide directly or through Cathepsin B cleavable spacers. Conjugates showed moderate in 
vitro cytostatic effect. Therefore, sequence modifications were performed by Ala-scan and 
positional scanning resulting in conjugates with much higher bioactivity. Conjugates in which 
Gly was replaced by amino acids with bulky apolaric side chains provided the best efficacy. 
The influence of the cellular uptake, stability and drug release on the anti-tumour activity was 
investigated. It was found that mainly the difference in the cellular uptake of the conjugates 
generated the distinct effect on cell viability. One of the most efficient conjugate Dau=Aoa-
LRRY-VHLFYAT-NH2 showed tumour growth inhibition on orthotopically developed HT-
29 colon cancer in mice with negligible toxic side effect compared to the free drug. We also 
indicate that this sequence is not specific to HT-29 cells, but it has a remarkable effect on 
many other cancer cells. Nevertheless, the Phe-containing conjugate was more active in all 
cases compared to the conjugate with the parent sequence. The literature data suggested that 
this sequence is highly overlapped with peptides that recognize Hsp70 membrane bound 
protein overexpressed in many types of tumours. 
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1. Introduction 
Colon cancer has become the third most commonly diagnosed cancer and the fourth leading 
cause of death related to cancer in the world [1, 2]. Besides the conventional treatments of 
colon cancer (surgery, radiation therapy and chemotherapy), targeted therapy is one of the 
main therapeutic approaches that might have significant role in the future [3]. The most 
remarkable advantages of targeted cancer therapy over the conventional chemotherapy are the 
specificity towards cancer cells while sparing toxicity to off-target cells and the avoidance of 
multi-drug resistance (MDR) that are the major obstacles in cancer chemotherapy [4]. The 
concept of selective drug targeting is based on the high expression of certain cell surface 
components on tumours or the tumour neovasculature [5]. The two main groups of targeting 
moieties are antibodies [6] and small homing peptides like peptide hormones [7, 8]. Peptides 
having high binding affinities to tumour selective or overexpressed receptors in cancer cells 
are useful because of their simple structure, low immunogenicity and easy, cost-effective 
chemical synthesis compared to antibody drug conjugates (ADCs). In the last decades, many 
developments have been done in the field of peptide based small molecule drug conjugates 
(SMDCs), particularly for cancer therapy [9]. However, the efficacy of these conjugates was 
studied rather individually on cancer cells. Nevertheless, the number of receptors in cancer 
cells is limited, therefore, the elevation of the drug conjugate concentration alone might not 
enhance the anti-tumour effect. To overcome this drawback, the combination of SMDCs 
could provide increased biological activity [10]. Therefore, the search of new tumour homing 
peptides is a hot topic in targeted cancer therapy [11]. One of the approach often used to 
explore new peptides is a technique belonging to in vitro evolution methods: phage display is 
a useful tool to identify tumour specific peptides that can be used efficiently for anti-cancer 
drug targeting [12]. 
Zhang and his co-workers selected HT-29 human colon cancer specific heptapeptides by 
phage display technology [13]. In the in vitro panning experiment, a 7-mer phage-display 
peptide library containing 10
11
 pfu was used (ca. 100 clones belong to one peptide sequence). 
After three rounds of panning using colon cancer cell lines and two rounds of subtractive 
screening, the peptide sequences of 50 randomly picked phage clones were analysed by cell – 
enzyme-linked immunosorbent assay. The heptapeptide VHLGYAT was found as the most 
selective peptide to HT-29 colon cancer cell line. It has to be noted that the receptor 
recognized by this peptide was not identified. 
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In our previous studies, gonadotropin-releasing hormone peptide derivative – drug conjugates 
were applied as drug delivery systems (DDS) for colon cancer treatment [14]. In in vitro 
experiments, the most efficient compounds in which daunomycin (Dau) was attached to 
modified lamprey GnRH-III via oxime linkage were Glp-His-Trp-Lys(Bu)-His-Asp-Trp-
Lys(Dau=Aoa)-Pro-Gly-NH2 and Glp-D-Tic-Lys(Bu)-His-Asp-Trp-Lys(Dau=Aoa)-Pro-Gly-
NH2 (where Glp is pyroglutamic acid, Bu is butyryl, Aoa is aminooxyacetyl moiety and Tic is 
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) [15, 16]. Daunomycin is attached to the side 
chain of Lys in position 8. This conjugate showed a pronounced cytostatic effect with a 2-3 
μM IC50 value on HT-29 cells in MTT assay. Furthermore, the first conjugate showed higher 
tumour growth inhibition and lower toxic side effects on orthotopically developed HT-29 
tumour bearing mice than the free Dau in maximal tolerated dose (40% inhibition instead of 
30%) [17]. It is worth mentioning that the oxime linkage is stable not only in human plasma 
(in contrast to ester bond) but also in the presence of Cathepsin B (an overexpressed 
lysosomal enzyme in cancer cells that plays role in the degradation of conjugates taken up by 
receptor mediated pathway) or in lysosomal homogenate. Therefore, the smallest metabolite 
released from conjugates is the daunomycin connected to an amino acid through oxime bond 
(Dau=Aoa-Aaa-OH), in the case of the above mentioned conjugates, it is H-Lys(Dau=Aoa)-
OH [18]. These metabolites bind to DNA as site of action, but with a bit lower efficacy than 
the free drug.  
For the improvement of tumour growth inhibition, we planned to develop further conjugates 
that can be used in combination for targeted cancer therapy. For this purpose, the VHLGYAT 
heptapeptide selected by Zhang et al. for HT-29 cells was chosen as homing device [13]. In 
this study, first we developed three conjugates and selected the most active one for further 
experiments. In addition, it was suspected that by the random selection of 50 clones from the 
panned and screened phages, some compounds with higher affinity and/or selectivity were 
lost. Thus, Ala scan and positional scan procedures were used to find more active conjugates. 
Next to the stability studies of the conjugates under circumstances used for in vitro and in vivo 
experiments, their degradation in lysosomal homogenate was investigated. Finally, two 
conjugates were selected for in vivo studies. In addition, we also report here that the peptide 
sequence was not selective to HT-29 cancer cells that might confirm the suggested target 
molecules which are overexpressed on most types of tumour cells. 
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2. Materials and methods 
2.1. Materials 
N,N′-diisopropylcarbodiimide (DIC), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1-
hydroxybenzotriazole hydrate (HOBt), triisopropylsilane (TIS) and ninhydrin were purchased 
from Sigma-Aldrich Kft. (Budapest, Hungary). All other reagents and solvents (anhydrous) 
were obtained from VWR International Kft. (Debrecen, Hungary). Fmoc-Rink Amide MBHA 
resin and all amino acid derivatives used in this study were purchased from Iris Biotech 
GmbH (Marktredwitz, Germany). Isopropylidene protected aminooxyacetic acid derivative 
was prepared in our laboratory [19]. 
2.2. Peptide synthesis and conjugation of Dau to peptide derivatives 
Peptides were prepared by solid phase peptide synthesis using the standard Fmoc/tBu 
procedure on Rink-Amide MBHA resin (for details, see Supporting Information Materials and 
methods section). After assembling the linear peptides, the isopropylidene protected 
aminooxyacetic acid (Aoa) was attached to their N-termini on the resin. The side chain 
unprotected peptides were cleaved from the resin as well as the removal of side chain 
protecting groups was made by treatment with 95% TFA, 2.5% TIS and 2.5% water (v/v/v) 
mixture. The yield of the purified peptide derivatives was between 45–60%. Prior to the 
conjugation, the isopropylidene protecting group from Aoa was removed with 1 M 
methoxyamine containing buffer solution as it is described in [19]. The reaction mixture was 
purified by RP-HPLC to separate the unprotected functionalized peptides and Dau was 
conjugated to the aminooxyacetylated peptides in 0.2 M NH4OAc solution (pH 5.0) at a 10 
mg/mL concentration. The conjugation ran almost quantitatively in all cases. The resulting 
conjugates were analysed by analytical RP-HPLC and electrospray ionization mass 
spectroscopy (ESI-MS). The purity of the conjugates was over 95% in all cases and no free 
Dau impurity was detected. 
2.3. Reverse phase high performance liquid chromatography (RP-HPLC) 
The crude peptides and conjugates were purified as described in [19]. Analytical RP-HPLC in 
case of conjugates 1-9 was performed as described in [19], for the rest of the conjugates a 
Macherey-Nagel Nucleosil C18 column (5 μm, 100 Å; 250×4.6 mm) (Macherey-Nagel 
GmbH & Co. Düren, Germany) column was used.  
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2.4. Mass spectrometry (MS)  
Electrospray ionization (ESI)-MS analyses were carried out as detailed in [19].  
LC-MS analyses were performed on a Q Exactive
TM
 Focus, high resolution and high mass 
accuracy, hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany) using on-line UHPLC coupling. UHPLC separation was performed on a Dionex 
3000 UHPLC system using a Supelco Ascentis C18 column (2.1 x 150 mm, 3 µm). Linear 
gradient elution (0 min 2% B, 1 min 2% B, 17 min 90% B) with eluent A (0.1% HCOOH in 
water, v/v) and eluent B (0.1% HCOOH in acetonitrile/water, 80:20, v/v) was used at a flow 
rate of 0.2 mL/min at 40 °C. High resolution mass spectra were acquired in the 200–1600 m/z 
range. LC-MS data were analysed by Xcalibur
TM
 software (Thermo Fisher Scientific) and 
with Origin Pro 8 (OriginLab Corp., Northampton, MA, USA). 
2.5. Stability studies 
To imitate the conditions used in cellular uptake studies and in vitro cytotoxicity assay, 
stability of the conjugates was measured in serum-free medium and 2.5% Fetal Bovine Serum 
(FBS) containing medium, respectively. Conjugates (30 µM) were incubated in the media at 
37 °C, samples were taken at 0 and 3 h (in case of serum-free medium) and at 0, 3, 6 and 24 h 
(in case of 2.5% FBS containing medium), aliquots were quenched with acetic acid. After 
lyophilisation, samples were prepared for LC-MS analyses using Pierce C18 spin columns 
(Thermo Fisher Scientific). 
The conditions of the in vivo studies were imitated by incubation of the conjugates in 90% 
human plasma derived from a healthy volunteer. The plasma stability study was carried out as 
can be seen in [16], except for the incubation times which were 0, 5 and 60 min.  
2.6. Metabolism in lysosomal homogenate 
The stability study in rat liver lysosomal homogenate is described in [16] with few 
exceptions: the concentration of the mixed conjugates and the rat liver lysosomal homogenate 
were both 0.05 µg/µL and aliquots were taken at 0, 1, 3, 6 and 24 h.  
2.7. Cell culturing and in vitro cytostatic effect studies 
HT-29 human colon adenocarcinoma cells were cultured as described in [20].  
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The description of the in vitro cytostatic effect study can be seen in [21], except for the 
incubation time with the conjugates that was in this case 24 h (followed by a washing step and 
48 h additional incubation).  
For the specificity study of the drug conjugates, the following cell lines were used: MDA-
MB-231 and MCF7 (human breast cancer), 4T1 (mouse breast cancer), DU145 and PC-3 
(human prostate cancer), OVCAR-3 (human ovarian cancer), Hep G2 (human liver cancer), 
A2058, WM983B and M24 (human melanoma), B16 (mouse melanoma), H1975, H1650 and 
A549 (human lung cancer), HT-29, HCT116 and WiDr (human colorectal adenocarcinoma), 
CT26.WT (mouse colon cancer), PANC-1 (human pancreatic cancer) which were cultured in 
RPMI-1640 medium, then U-87 MG (human malignant glioma) and MRC-5 (human 
fibroblast) which were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Lonza) and 
PE/CA-PJ15 and PE/CA-PJ41 (human oral cancer) which were cultured in Iscove's Modified 
Dulbecco's Medium (IMEM) (Sigma-Aldrich). All mediums were supplemented with 10% 
heat-inactivated FBS (Euro Clone, Pero, Italy) (20% FBS for OVCAR-3 cell line) and with 
1% penicillin/streptomycin (Sigma-Aldrich). Cell lines were obtained from ATCC, except for 
PE/CA-PJ15, PE/CA-PJ41 (ECACC), A2058 (kindly provided by L. A. Liotta, NCI, 
Bethesda, MD, USA), M24 (kind gift from B. M. Mueller, Scripps Research Institute, La 
Jolla, CA, USA) and WM983B (kindly provided by Meenhard Herlyn, Wistar Institute, 
Philadelphia, PA, USA). Cells were cultured in sterile T25 flasks with ventilation cap 
(Sarstedt, Nümbrecht, Germany) at 37 °C in a humidified atmosphere with 5% CO2.  
The in vitro cytostatic effect on these cell lines was measured using MTT assay, similarly as 
described above. Cells were seeded at a density of 3 × 103 - 10 × 103 cells per well (dependent 
on the cell line). At the end of the measurement, absorbance values of treated samples were 
normalized versus untreated control samples and interpolated by nonlinear regression analysis 
with Prism 6 software (GraphPad, La Jolla, CA, USA) to generate dose-response curves.  
2.8. Cellular uptake determination by flow cytometry 
For determining cellular uptake of the bioconjugates by HT-29 cells, flow cytometry was used 
(details can be seen in [21]), except for the incubation time with the conjugates that was 3 h. 
2.9. Confocal microscopy imaging 
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Intracellular localization studies were conducted with a Zeiss 710 confocal microscope (Carl 
Zeiss Microscopy, Jena, Germany), as described in [22]. Briefly, Dau-peptide conjugates 
were added to a final concentration of 50 µM in RPMI medium to the cells and incubated for 
90 min. For co-localization experiments, organelle specific fluorescent labels were used to 
stain lysosomes and mitochondria (LysoTracker Deep Red and MitoTracker Deep Red, 
Molecular Probes (Eugene, OR, USA)). Samples containing the Dau-peptide conjugates were 
excited at 488 nm while detecting the fluorescence emission between 550-600 nm. In the case 
of lysotracker and mitotracker, the excitation wavelength was 633 nm and detection interval 
was 680-730 nm. The acquired images were elaborated with ZEN lite software (Zeiss 
Microscopy).  
2.10. In vivo anti-tumour effect of conjugates on orthotopical human HT-29 colon 
carcinoma bearing SCID mice 
6–8 weeks old, immunodeficient SCID female mice (weighing 22–27 g) were used in this 
experiment. Tumour development and transplantation was performed by using HT-29 colon 
carcinoma cells (obtained from ATCC and cultured according to their standards), the 
procedure is detailed in [17]. The treatments started 13 days after tumour transplantation by 
intraperitoneal administration of the compounds dissolved in distilled water for injection 
(Pharmamagist Kft., Budapest, Hungary). For the treatment, 8–8 mice/group were used. One 
group of mice were treated with free Dau (1 mg/kg body weight) on days 13 and 20 after 
tumour transplantation. Groups that received conjugates (3) and (13) were treated with a dose 
of 10 mg/kg Dau content (36.6 and 38.3 mg/kg of each conjugate, respectively) on days 13, 
16, 20, 23 and 27 after tumour transplantation. Control group was treated with solvent. The 
experiment was terminated on day 30 after tumour transplantation. Daunomycin group was 
terminated on day 23 after tumour transplantation due to significant weight loss of the 
animals. The mice from all groups were killed by cervical dislocation. Their tumours and 
livers were removed and weighed. The animals used in these studies were cared for according 
to the ‘Guiding Principles for the Care and Use of Animals’ based upon the Helsinki 
declaration, and they were approved by the local ethical committee. Permission license for 
breeding and performing experiments with laboratory animals: PEI/001/1738-3/2015 and 
PEI/001/2574–6/2015. 
2.11. Immunohistochemical staining and scoring of Ki-67 
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Monoclonal mouse antibody against human Ki-67 (DAKO, Glostrup, Denmark) was applied. 
The routinely formalin-fixed tumours were dehydrated in a graded series of ethanol, 
infiltrated with xylene and embedded into paraffin at a temperature not exceeding 60 °C. Two 
micron thick sections were mounted on Superfrost slides (Thermo Shandon, Runcorn, UK) 
and were manually deparaffinized. To block endogenous peroxidase activity, slides were 
treated for 20 min at room temperature with 3% H2O2 in methanol. Slides were immersed in 
6% citrate buffer (pH 6) and exposed to 98 °C water bath for 40 min. Slides were primarily 
treated with antibody against human Ki-67 (1:40) and incubated for 1 hour at room 
temperature. After washing, secondary antibody Biotinylated Link (Dako) was applied (10 
min at room temperature). For visualization, supersensitive one step polymer HRP (Biogenex, 
Fremont, California, USA) was used with AEC as chromogen. Staining without the primary 
antibody served as negative control. No significant background staining was detectable. The 
Ki-67-positive tumour cells per fields of vision were counted manually under light 
microscope (40-fold magnification), 5 fields of vision per tumour were evaluated. 
Proliferation index was calculated as percentage of Ki-67 positive cells from all cells in the 
field of view. 
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3. Results 
3.1. Synthesis of VHLGYAT peptide containing daunomycin conjugates 
Three daunomycin conjugates of VHLGYAT peptide amide (Dau=Aoa-VHLGYAT-NH2, 
Dau=Aoa-GFLG-VHLGYAT-NH2, Dau=Aoa-LRRY-VHLGYAT-NH2) were prepared. Dau 
was attached directly to the N-terminus of the peptide or to a Cathepsin B cleavable spacer 
incorporated between the homing peptide and Dau. Two different spacers were applied 
(GFLG and LRRY). The peptides were built up on solid support manually using standard 
Fmoc/tBu strategy. The N-terminus of the linear peptides was modified with aminooxyacetyl 
moiety (Aoa) as a conjugation site. However, Aoa is very sensitive to aldehydes and ketones 
that results in difficulties concerning the final cleavage step and working up procedure. 
Therefore, Aoa was incorporated as isopropylidene protected derivative to the peptides. This 
protection was removed with 1 M methoxyamine under slightly acidic condition prior to the 
Dau conjugation (Scheme 1). All synthetic steps ran accordingly and the synthesis of 
conjugates resulted in good yields. The characteristics of the conjugates are presented in 
Table 1.  
 
Scheme 1. Synthesis of oxime linked daunomycin – homing peptide conjugates 
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Table 1. Characteristics of VHLGYAT peptide containing daunomycin conjugates. RP-HPLC spectra of the 
conjugates can be seen in Supplementary information S1. 
Compounds (code) RP-HPLC 
Rt (min)
a
 
ESI-MS 
calculated 
ESI-MS 
measured
b
 
Dau=Aoa-VHLGYAT-NH2 (1) 26.1 1340.8 1341.0 
Dau=Aoa-GFLG-VHLGYAT-NH2 (2) 32.5 1715.8 1715.7 
Dau=Aoa-LRRY-VHLGYAT-NH2 (3) 28.2 1930.1 1929.9 
a
RP-HPLC: column: Phenomenex Aeris Peptide XB-C18 column (250 mm x 4.6 mm) with 3.6 μm; 
eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (80:20, v/v) (B); gradient: 0 min 0% B, 5 min 0% 
B, 50 min 90% B; flow rate: 1 mL/min; detection: λ= 220 nm. 
b
ESI-MS: Esquire 3000+ ion trap mass spectrometer 
 
3.2. In vitro cytostasis and cellular uptake of the VHLGYAT based drug 
conjugates 
The in vitro cytostatic effect was measured on HT-29 human colon cancer cells. Cells were 
treated with the conjugates for 6 h or 24 h, then the cells were washed and incubated further. 
After 72 h (including the treatment period), MTT assay was used for the determination of the 
cytostatic effect of the conjugates. When the cells were treated with the conjugates for 6 h, 
only the Dau=Aoa-LRRY-VHLGYAT-NH2 (3) conjugate showed moderate cytostatic effect 
(IC50 = 62.7 μM) that improved a bit during longer treatment time.  
According to these results and the low solubility of conjugate 2, we selected conjugate 3 as 
control conjugate for further studies (and for the subsequent assays, 24 h tretament time was 
used). 
3.3. Synthesis of conjugates using Ala scan in the sequence of homing peptide 
During the next step, all amino acids, except alanine were replaced by Ala one by one in the 
sequence of the homing peptide VHLGYAT. The six new conjugates were prepared as it was 
described above. The characteristics of the Ala scanned conjugates are summarized in Table 
2.  
  
13 
 
Table 2. Characteristics of conjugates modified by Ala scan. RP-HPLC spectra of the conjugates can be seen in 
Supplementary information S2. 
Compounds (code) RP-HPLC 
Rt (min)
a
 
ESI-MS 
calculated 
ESI-MS 
measured
b
 
IC50 
(μM)* 
Dau=Aoa-LRRY-AHLGYAT-NH2 (4) 27.7 1901.5 1901.8 >100 
Dau=Aoa-LRRY-VALGYAT-NH2 (5) 29.0 1863.5 1864.0 36.8±0.4 
Dau=Aoa-LRRY-VHAGYAT-NH2 (6) 27.2 1887.5 1887.8 >100 
Dau=Aoa-LRRY-VHLAYAT-NH2 (7) 28.6 1943.6 1943.9 24.1±1.6 
Dau=Aoa-LRRY-VHLGAAT-NH2 (8) 27.4 1837.5 1837.8 >100 
Dau=Aoa-LRRY-VHLGYAA-NH2 (9) 28.0 1899.8 1899.9 70.9±3.8 
a
RP-HPLC: column: Phenomenex Aeris Peptide XB-C18 column (250 mm x 4.6 mm) with 3.6 μm; 
eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water (80:20, v/v) (B); gradient: 0 min 0% B, 5 
min 0% B, 50 min 90% B; flow rate: 1 mL/min; detection: λ= 220 nm. 
b
ESI-MS: Esquire 3000+ ion trap mass spectrometer 
*Note that IC50 value of conjugate 3 was 46.9±9.4 µM in these experiments. 
3.4. In vitro cytostasis and cellular uptake of conjugates using Ala scan in the 
sequence of homing peptide 
The study of the cytostatic effect of the Ala scanned conjugates was investigated using HT-29 
colon cancer cells and compared with the conjugate Dau=Aoa-LRRY-VHLGYAT-NH2. The 
results indicated that the replacement of Val, Leu or Tyr to Ala (V/A (4), L/A (6), Y/A (8)) in 
the sequence of the homing peptide is not allowed without loss of cytostatic effect (IC50 > 100 
μM). When Thr was changed to Ala (T/A (9)), the anti-tumour effect decreased a bit, while 
the modification of His (H/A (5)) in the sequence resulted in a slightly more active conjugate 
(Table 2). The replacement of Gly to Ala (G/A (7)) increased the cytostatic effect 
significantly (from IC50 = 46.9±9.4 μM to 24.1±1.6 μM) in this experiment.  
The correlation between the cytostatic effect and the cellular uptake of the conjugates was 
investigated by flow cytometry. The percentage of the Dau positive cells (cellular uptake) and 
the fluorescence mean values of the cells were determined. The cells were treated with 100 
μM conjugates for 3 h. About 80% of cells were Dau+ in case of G/A (7) conjugate which 
was higher than the conjugate with the parent homing peptide (ca. 70%). The observed 
difference was even more remarkable concerning fluorescence intensity values, suggesting 
higher cellular uptake of G/A (7) conjugate by cells. The other conjugates showed lower 
cellular uptake in the following decreasing order: T/A (9), V/A (4), H/A (5) (this contradicts a 
bit with cytostatic effect), L/A (6), and Y/A (8) (Fig. 1). 
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Figure 1. Cellular uptake of the conjugates prepared by Ala scan using flow cytometry and HT-29 colon cancer 
cells. The concentration of the drug conjugates was 100 µM. Experiments were performed in duplicates (error 
bars represent standard deviation). 
3.5. Synthesis of conjugates using positional scanning in position 4 of the homing 
peptide 
The results of the Ala scan indicate that the modification of position 4 has major effect on 
cellular uptake and cytotoxicity. Therefore, the Gly in position 4 of the homing motif was 
replaced by ten amino acids with different characteristics. Lys as a basic, Glu as an acidic 
amino acid, Thr, Ser, Tyr and Asn as polar and Phe, Cpa (p-chlorophenylalanine) and Leu as 
nonpolar (aromatic and nonaromatic) amino acids were incorporated. Furthermore, Pro that 
might break the conformation of the peptide was also investigated. The synthesis of the 
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peptides and conjugates was carried out in the same way as it was described before. The 
characteristics of the conjugates are summarized in Table 3. 
Table 3. Characteristics of conjugates modified by positional scanning in position 4. RP-HPLC spectra of the 
conjugates can be seen in Supplementary information S3. 
Compounds (code) RP-HPLC 
Rt (min)
a
 
ESI-MS 
calculated 
ESI-MS 
measured
b
 
IC50 
(μM)* 
Dau=Aoa-LRRY-VHLKYAT-NH2 (10) 28.2 2000.7 2000.8 50.3±3.0 
Dau=Aoa-LRRY-VHLEYAT-NH2 (11) 29.3 2001.6 2001.7 29.5±6.3 
Dau=Aoa-LRRY-VHLLYAT-NH2 (12) 31.1 1985.7 1986.0 7.5±3.5 
Dau=Aoa-LRRY-VHLFYAT-NH2 (13) 31.2 2019.7 2019.8 6.6±2.9 
Dau=Aoa-LRRY-VHLSYAT-NH2 (14) 28.9 1959.6 1959.8 24.8±7.4 
Dau=Aoa-LRRY-VHLTYAT-NH2 (15) 29.0 1973.6 1974.0 21.7±6.5 
Dau=Aoa-LRRY-VHLNYAT-NH2 (16) 29.0 1986.6 1986.9 28.0±19.4 
Dau=Aoa-LRRY-VHLPYAT-NH2 (17) 31.2 1969.7 1970.1 >50 
Dau=Aoa-LRRY-VHLYYAT-NH2 (18) 30.8 2035.7 2036.1 38.4±17.7 
Dau=Aoa-LRRY-VHLCpaYAT-NH2 (19) 31.3 2053.6 2053.8 3.6±0.1 
a
RP-HPLC: column: Macherey-Nagel Nucleosil C18 column (5 μm, 100 Å; 250×4.6 mm) 
eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water (80:20, v/v) (B); gradient: 0 min 0% B, 5 
min 0% B, 50 min 90% B; flow rate: 1 mL/min; detection: λ= 220 nm. 
b
ESI-MS: Esquire 3000+ ion trap mass spectrometer 
*Note that in these experiments, IC50 value of conjugates 3 and 7 were 39.4±5.9 and 27.9±6.4, respectively. 
3.6. In vitro cytostasis and cellular uptake of conjugates using positional scanning 
in position 4 of the homing peptide 
All conjugates, except the Pro containing one showed cytostatic effect in the measured range 
(Table 3). The incorporation of Lys in this position decreased the cytostatic effect (IC50 = 
50.3±3.0 μM) compared to both G/A (7), and the native parent (3) conjugates (IC50 = 
27.9±6.4 and 39.4±6.4, respectively). No significant difference in cytostatic effect was 
observed when the Ala was replaced by Thr (15), Ser (14), Asn (16) and Glu (11). However, 
it is worth to mention that the change of Ala to Ser increased the water solubility of the 
conjugate that might be useful in drug development. The results indicate that the 
incorporation of Phe (13) or Leu (12) gives the best conjugates, having 4-5 times higher 
cytostatic effect than the G/A (7) or the parent (3) conjugates (IC50 = 6.6±2.9 μM and 7.5±3.5 
μM, respectively). The chlorine substitution on aromatic ring of Phe (13) decreased (IC50 = 
3.6±0.1 μM), while the replacement of Phe by the more polar Tyr (18) increased (IC50 = 
38.4±17.7 μM) the IC50 value.  
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We also studied the effect of the peptides without the drug (Dau) in case of (3) and (13). As a 
result, no effect of the peptides alone could be detected (IC50 > 100 µM). 
Cellular uptake of the Dau-peptide conjugates (G/A (7), G/F (13), G/S (14), G/P (17)) was 
studied first by confocal microscopy. Lysosomes and mitochondria were stained with specific 
fluorescent probes to identify the intracellular localization of the conjugates and the released 
metabolite.  
The free Dau was taken up by cells fast and localized partly in the nucleus (Fig. 2A). 
Conjugate 13 showed a similar pattern of subcellular distribution: it exhibited a 
predominantly punctate pattern in cytoplasmic compartments (Fig. 2B). In the case of 
conjugate 14, a weaker signal could be detected (Fig. 3). The conjugate could be detected in 
cytoplasmic compartments in case of living cells, however, it accumulated in the nucleus of 
dying cells (Fig. 3). Conjugate 17 exhibited an overall weaker signal than the other two 
derivatives (Fig. 2C).  
 
Figure 2. Cellular uptake of drug conjugates studied by confocal microscopy. (A, B, C) Uptake of free Dau, 
drug conjugates G/F (13) and G/P (17), respectively by HT-29 colon cancer cells. Cells were incubated with 50 
µM Dau or drug conjugate for 90 min. The conjugates were detected at 550-600 nm (emission wavelength of 
daunomycin, marked by yellow). The scale bar represents 10 µm. 
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Figure 3. Comparison of phenotype of living and dead HT-29 colon cancer cells incubated with G/S (14) drug 
conjugate (incubation time: 90 min) studied by confocal microscopy. Image captured in transmitted light mode 
can be seen on the left. The conjugate was detected at 550-600 nm (emission wavelength of daunomycin, marked 
by yellow, on the right). The scale bar represents 10 µm. 
Conjugate 13 was applied together with specific fluorescent dyes to follow the intracellular 
localization of Dau-containing derivatives. Localization of Dau-derivatives is represented in 
yellow, lysosome and mitochondrion specific labels with green and red, respectively. 
Common loci can be explored in the overlay images. The images reveal co-localization with 
lysosome specific fluorescent stain Lysotracker Deep Red, but not with mitochondria (Fig. 4).  
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Figure 4. Study of cellular uptake of drug conjugate G/F (13) (yellow) by HT-29 colon cancer cells using 
confocal microscopy. Lysosomes were stained with Lysotracker Deep Red (upper panel, green), mitochondria 
were stained with MitoTracker Deep Red (lower panel, red). Cells were incubated with 50 µM drug conjugate 
for 30 min before imaging. The conjugate was detected at 550-600 nm (emission wavelength of daunomycin, 
marked by yellow). The scale bar represents 10 µm. 
3.7. Synthesis of conjugates using positional scanning in position 6 of the homing 
peptide 
The Ala in the homing peptide sequence that was not changed during Ala scanning, was 
replaced with different amino acids to see their influence on the biological activity. However, 
the starting conjugate for this was conjugate 13 containing Phe in position 4 of homing 
peptide. Similar to the previous positional scanning experiment Lys, Glu, Ser, Leu, Asn and 
Pro were incorporated to the place of Ala (Table 4). The synthesis and characterization were 
investigated as they were described above.  
Table 4. Characteristics of conjugates modified by positional scanning in position 6. RP-HPLC spectra of the 
conjugates can be seen in Supplementary information S4. 
Compounds (code) RP-HPLC 
Rt (min) 
ESI-MS 
calculated 
ESI-MS 
measured 
IC50 
(μM) 
Dau=Aoa-LRRY-VHLFYKT-NH2 (20) 30.5 2077.3 2077.8 11.5±1.7 
Dau=Aoa-LRRY-VHLFYET-NH2 (21) 31.9 2078.3 2078.5 54.3±13.4 
Dau=Aoa-LRRY-VHLFYLT-NH2 (22) 32.3 2062.3 2062.7 3.2±0.1 
Dau=Aoa-LRRY-VHLFYST-NH2 (23) 32.1 2036.2 2036.7 17.7±2,2 
Dau=Aoa-LRRY-VHLFYNT-NH2 (24) 31.8 2063.3 2063.7 15.4±6.3 
Dau=Aoa-LRRY-VHLFYPT-NH2 (25) 31.6 2046.3 2046.8 10.9±0.9 
a
RP-HPLC: column: Macherey-Nagel Nucleosil C18 column (5 μm, 100 Å; 250×4.6 mm) 
eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water (80:20, v/v) (B); gradient: 0 min 0% B, 5 
min 0% B, 50 min 90% B; flow rate: 1 mL/min; detection: λ= 220 nm. 
b
ESI-MS: Esquire 3000+ ion trap mass spectrometer 
*IC50 value of conjugate 13 was 6.5±0.3 in this experiment. 
3.8. In vitro cytostasis of conjugates using positional scanning in position 6 of the 
homing peptide 
The replacement of Ala in position 6 of the homing peptide by different amino acids had 
lower influence on the cytostatic effect of the conjugates (Table 4) except for the 
incorporation of Glu (21), that decreased the effect significantly (IC50 = 54.3±13.4 μM). Only 
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the replacement of Ala to Leu (22) enhanced the cytostatic effect (IC50 = 3.2±0.1 μM, half of 
that for conjugate 13).  
3.9. In vitro cellular uptake of conjugates using positional scanning in position 4 
and 6 of the homing peptide 
Four conjugates (G/F (13), G/S (14), G/P (17) and G/Cpa (19),) were selected from the group 
of conjugates that were modified in position 4 and one conjugate ((G/F, A/L (22)) was 
selected from the last group (scanned in position 6) for cellular uptake studies. The conjugates 
were compared with the parent sequence (3) containing and G/A (7) conjugates. All 
conjugates were applied in 6.25 μM to 100 μM concentrations. The G/F conjugate (13) that 
had one of the highest cytostatic effect entered the cells also at a lowest concentration and its 
uptake increased with the elevation of the concentration (Fig. 5). Interestingly, the cellular 
uptake of 13 was a bit higher than of conjugate G/Cpa (19) that had slightly better cytostatic 
effect. Significant uptake of G/A (7) and G/S (14) could be detected only at 25 μM 
concentration, the previous one showing higher uptake. The G/P (17) conjugate that did not 
show cytostatic effect in the measured range, could not enter the cells efficiently even at a 
high, 100 μM concentration. At the highest concentrations, the toxic effect of conjugate 13 
and 19 was observed resulting in significantly lower number of living cells that decreased the 
measured fluorescence intensity. A/L change in position 6 (conjugate 22) resulted in similar, 
but a bit lower cellular uptake than conjugate 13 and 19 (Fig. 5). 
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Figure 5. Comparison of the cellular uptake of drug conjugates G/F (13), G/S (14), G/P (17) and G/Cpa (19) and 
G/F, A/L (22) with parent conjugate (3) and G/A (7) using flow cytometry on HT-29 colon cancer cells. 
Experiments were performed in duplicates (error bars represent standard deviation).  
 
3.10. Stability of the conjugates 
The stability of selected conjugates (3, 7, 13, 14, 17, 19, 22) was studied in serum free 
incomplete cell culture medium at 37 °C that was applied for in vitro cellular uptake 
experiments. Samples were taken at zero time point just after the addition of the conjugates 
into the medium and after 3 h which is the endpoint of the cellular uptake measurements. 
According to the HPLC-MS spectra, none of the conjugates showed any decomposition under 
these circumstances (Supplementary information S5-S11). In addition, their stability was 
examined in 2.5% serum containing complete cell culture medium at 37 °C, as these 
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conditions were used in the in vitro cell viability measurements. Because 24 h treatment was 
applied in cell viability assays and then the conjugates were washed out from the cells, the 
stability experiments were continued for 24 h in this case. Samples were taken at zero time 
point, 3 h, 6 h and 24 h. Only parent conjugate (3) and the less active Pro-containing 
conjugate showed minor decomposition that could be detected rather at 24 h (Supplementary 
information S9). The observed cleavage point was between the two Arg in the spacer 
sequence resulting in Dau=Aoa-LR-OH and H-RYVHLXYAT-NH2 (where X is Gly (3) or 
Pro (17). Interestingly, significant sugar loss of conjugate 17 was also detected. According to 
this data, we can conclude that the conjugates are stable enough (except the Pro-containing 
one) not to influence the in vitro cellular uptake and cell viability studies. 
3.11. Active metabolite release from the conjugates in lysosomal homogenate 
The release of the active metabolite from the parent (3) and the most active (13, 19, 22) 
conjugates was investigated in rat liver lysosomal homogenate. Very fast decomposition was 
observed in all cases that did not depend on the sequence of the homing peptide (Fig. 6 and 
Supplementary information S12-S14). The main cleavage site in the spacer sequence was 
between the two Arg that appeared at zero time point. After 1 h Dau=Aoa-Leu-OH could be 
detected that increased in time while the quantity of Dau=Aoa-Leu-Arg-OH decreased. At 24 
h, only the smallest Dau-containing metabolite was observed. It is worth to note that the main 
cleavage site in the homing peptide was between Leu-X (X is Gly or its substituted amino 
acid) that was identified immediately at the zero time point. Interestingly, only this cleavage 
site was observed in 0.2 M NaOAc solution (pH 5) as control solution, but only at 24 h (data 
not shown). 
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Figure 6. Stability of Dau=Aoa-LRRY-VHLGYAT (3) in rat liver lysosomal homogenate monitored by LC-MS. 
Note that reaction termination in case of the “Starting point” sample took place after ~1 min. (1 [M+2H]2+, 2 
[M+H]
+
.) 
3.12. Study of the tumour type specificity of conjugate 3 and 13 
Tumour type specificity of conjugates 3 and 13 was investigated on 22 different types of 
tumour cell line and on MRC-5 (human fibroblast) as non-tumouricidal control cell line. The 
cells were treated with the compounds for 24 h followed by incubation in fresh medium for 
further 48 h. The IC50 values of the conjugates were compared to each other and to the values 
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received by measuring the effect of the free drug molecule (Table 5). The data indicate that 
the conjugates had cytostatic effect on all cell types, but the lowest activity was measured on 
MRC-5 cells. However, the conjugates were not selective to the HT-29 human colon 
adenocarcinoma at all. Nevertheless, conjugate 13 showed higher cytostatic effect in all cases, 
that was ca. 1.5–5 times higher activity depending on the type of cancer cells. The IC50 values 
were mainly at the low micromolar range and they were 1-2 order of magnitude higher 
compared to the free Dau that can enter cells by diffusion.  
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Table 5. Specificity study of the cytostatic effect of drug conjugates 3 and G/F (13) compared to free Dau on 
various cell lines.  
Tumour type Cell line 
Dau 
(IC50; nM) 
Conjugate 3 
(IC50; μM) 
Conj. 
3 / 
Dau 
Conjugate 13 
(IC50; μM) 
Conj. 
13 / 
Dau 
Conj. 
3/ 
Conj. 
13 
Brain 
glioblastoma 
U-87 MG 27.9±3.5 14.2±3.5 510.3 6.6±0.2 236.9 2.15 
Breast 
adenocarcinoma 
MCF7 286.0±24.7 22.2±9.2 77.6 11.1±3.8 38.8 2 
Breast 
adenocarcinoma 
MDA-
MB-231 
52.9±10.3 6.3±2.5 118.8 4.6±0.8 86.6 1.37 
Mouse breast 
cancer 
4T1 40.8±6.8 34.2±0.4 837.4 11.6±3.6 284.6 2.95 
Colon carcinoma HCT 116 127.1±21.9 33.6±4.4 264.1 7.2±0.3 57 4.67 
Colon 
adenocarcinoma 
HT-29 202.9 ±1.0 30.1±0.3 148.3 11.6±0.1 57.1 2.6 
Colon 
adenocarcinoma 
WiDr 240.1±36.3 34.1±3.2 141.8 15.1±2.9 62.8 2.26 
Mouse colon 
carcinoma 
CT26.WT 126.0±46.8 15.8±2.5 125.7 8.3±1.0 66 1.9 
Hepatocellular 
carcinoma 
Hep G2 21.3±0.9 22.4± 4.4 1052.6 4.7±0.5 220.2 4.77 
Lung carcinoma A549 68.2±22.7 25.9±2.3 380.1 5.9±1.5 86.1 4.39 
Lung 
adenocarcinoma 
H1650 47.5±1.6 4.4±1.2 92.6 2.9±0.6 60.1 1.52 
Lung 
adenocarcinoma 
H1975 13.3±4.7 19.3±0.1 1458.7 3.7±0.8 279.9 5.22 
Melanoma A2058 33.3±0.4 10.5±5.8 316.8 3.5±1.3 104.5 3 
Melanoma M24 93.6±25.8 15.4±3.7 164.3 5.8±0.9 61.7 2.66 
Melanoma WM983B 44.3±19.2 7.1±2.5 159.8 5.1±0.4 114.6 1.39 
Mouse melanoma B16 8.9±5.4 15.2±3.0 1711.3 3.0±0.5 335.4 5.07 
Oral squamous 
cell carcinoma 
PE/CA 
PJ15 
26.7±5.0 20.2±4.6 759.3 7.4±3.4 277.3 2.73 
Oral squamous 
cell carcinoma 
PE/CA 
PJ41 
25.8±5.4 9.4±3.5 363.9 4.3±0.1 165.7 2.19 
Ovarian 
adenocarcinoma 
OVCAR-
3 
472.9±63.6 13.8±0.5 29.3 11.3±2.6 24 1.22 
Pancreas 
epithelioid 
carcinoma 
PANC-1 466.7±36.6 31.7±4.5 68 26.9±8.1 57.7 1.18 
Prostate 
carcinoma 
DU 145 24.5±5.4 6.1±2.2 249.7 3.5±0.5 142.3 1.74 
Prostate 
adenocarcinoma 
PC-3 26.0±7.1 20.5±0.3 787.5 5.9±1.6 226.7 3.48 
Normal fibroblast MRC-5 254.7±0.6 39.3±24.6 154.2 52.1±1.7 204.6 0.75 
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3.13. In vivo tumour growth inhibition 
Next to the parent conjugate 3, one of the most active conjugate 13 was selected for in vivo 
experiments. Conjugate 13 had a bit higher solubility than conjugates 19 and 22 and no 
significant additional advantages of the latter ones were observed. Prior to the in vivo 
experiments, the plasma stability of the conjugates was determined in 90% human plasma. 
Unfortunately, the peptide – drug conjugates might adsorb to the plasma proteins, therefore, it 
is difficult to make an exact conclusion for plasma stability. However, the intact conjugate 13 
could be still detected after 1 h by HPLC-MS while the parent conjugate 3 not 
(Supplementary information S15). The treatments were started on day 13 and the mice were 
terminated on day 30 after tumour transplantation, except for the free drug (Dau) group, 
which was terminated on day 23 after tumour transplantation due to the significant weight 
loss of the animals. The free drug (Dau) was administered i.p. using 1 mg/kg dose once a 
week that is the maximal tolerated dose in this case. Conjugates were injected at a dose of 10 
mg/kg Dau-content three times in the first and two times in the second week. During the 
experiment, one animal died from both the control and Dau treated groups, while two of them 
from the group treated with conjugate 3. In contrast, no animals died from the group treated 
with conjugate 13. After the termination, tumour growth inhibition was calculated by the 
measurement of tumour weight, while liver toxicity of the compounds was determined 
according to the liver weight. Animal weights did not differ from control mice in case of 
conjugates 3 and 13, while Dau-treated mice showed an incraesed weight loss. Animal weight 
data can be seen in the Supplementary information (S16). The results indicate that free Dau 
caused 84% tumour growth inhibition compared to the untreated control group (Fig. 7A), but 
it showed significant liver toxicity according to the loss of liver weight (28%). Similarly to 
the in vitro data, conjugate 13 was also more active in vivo in comparison with conjugate 3. In 
comparison with the control group, tumour growth inhibition was significant (89%) in case of 
conjugate 13, and not significant (65%) in case of conjugate 3. Inhibition effect on tumour 
growth of conjugate 13, in comparison with conjugate 3, was on the border of significance (p 
= 0.0593). The liver mass changes were 10% and 1%, respectively, that was not significant 
compared to the control group, and significantly different than it was observed in case of the 
free Dau treated group (Fig. 7B). 
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Figure 7. Comparison of tumour (A) and liver (B) weights during in vivo tumour growth inhibition experiment. 
8-8 mice per group were treated with solvent, free Dau, drug conjugates 3 or 13 from day 13 after tumour 
transplantation (established by HT-29 colon cancer cells). Tumours and livers were weighed after termination of 
the treatments. Note that daunomycin group was terminated on day 23 after tumour transplantation due to 
significant weight loss of the animals. Bars represent average of weights ± standard error of mean (note that 
because of the death of some animals before termination, N = 7, 7, 6 and 8 from left to right). Statistical analysis 
was performed by Mann-Whitney test. *, ** and *** mean significant at p<0.05, p<0.01 and p<0.001, 
respectively.  
To reveal the mechanism of the in vivo effect of conjugates and free drug (Dau), xenograft 
tumours were analysed by immunohistochemistry. The proportion of proliferating tumour 
cells was determined by Ki-67 labelling, which is a specific cellular marker for proliferation. 
Proliferation index was determined as % of Ki-67-positive cells per field of vision. Both 
conjugates significantly inhibited the number of Ki-67-positive cells in the xenograft tumour, 
in comparison with control tumours, where conjugate 13 inhibited at a higher degree, while 
free drug (Dau) did not inhibit significantly. Conjugate 13 significantly inhibited the number 
of Ki-67-positive cells in comparison with conjugate 3 and free drug (Dau) (Fig. 8). 
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Figure 8. Comparison of the proportion of proliferating tumour cells using Ki-67 as a marker of cell 
proliferation. Immunodeficient SCID mice were treated with solvent (control), free Dau or drug conjugates 3 or 
13 from day 13 after tumour transplantation using HT-29 colon cancer cells. After termination of the in vivo 
tumour growth inhibition experiment, tumours were fixed, embedded and stained by anti-Ki-67 antibody. Note 
that daunomycin group was terminated on day 23 after tumour transplantation due to significant weight loss of 
the animals. Proliferation index was calculated as % of Ki-67 positive cells from all cells in the field of view of 
the light microscope. Bars represent the average of 5 field of views of tumours of at least 3 animals per group ± 
standard error of mean. Statistical analysis was performed by Mann-Whitney test. *, **, *** and **** mean 
significant difference at p<0.05, p<0.01, p<0.001 and p<0.0001, respectively. 
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4. Discussion 
Targeted tumour chemotherapy might be an efficient tool for cancer treatment. Development 
of peptide based SMDCs is a current topic in this field. In spite of the higher tissue 
penetration of these conjugates over ADCs, the uptake of appropriate amount of drug 
molecules is still questionable. Therefore, a combination of peptide based SMDCs might be 
necessary for effective tumour regression in vivo. The most effective combination might be 
conjugates that contain different homing peptides recognizing different cell surface 
compartments attached to different drug molecules with various site of action. One of the 
approaches to find tumour selective peptides is phage display technique. In our research, 
homing peptides with selectivity to HT-29 human colon adenocarcinoma were searched in the 
literature. According to the finding by Zhang et al. [13], we selected the VHLGYAT 
heptapeptide as homing moiety that was identified from phage library. However, we believed 
that the sequence could be optimized for better tumour recognition.  
In the first trial, daunomycin was conjugated to the heptapeptide directly or through two 
different Cathepsin B cleavable linkers (GFLG or LRRY) via oxime linkage. The highest 
anti-tumour activity was observed in case of LRRY spacer containing conjugate that had the 
highest solubility as well. The results prompted us to use the LRRY spacer in our sequence 
modified conjugates in the further experiments. Thus, the LRRY spacer was applied for 
further conjugates that allows the release of the same metabolite in all cases that is important 
to compare the biological activity of the conjugates.  
In the next step, Ala-scan was performed to identify the positions in the sequence that can be 
modified. Altogether, we could conclude that the Gly in position 4 of the homing motif can be 
modified to have better cytotoxic effect, therefore, in the further experiments this amino acid 
was replaced by other different amino acids (positional scanning). The results of these 
experiments suggested that a bulky nonpolar amino acid (Leu, Phe, Cpa) in position 4 of the 
homing moiety is the best choice to increase the anti-tumour activity of the conjugates 
developed for HT-29 colon cancer. Because Ala in position 6 of the homing peptide was not 
changed by Ala-scan, we wanted to check the importance of this position as well. The 
incorporation of different amino acids showed no significant influence on biological activity, 
but an apolar amino acid in this position is also preferred.  
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One of the key point of the biological effect of the conjugates is their efficient entry into the 
cells. The cellular uptake experiments indicate that the cytostatic effect and the uptake of the 
conjugates correlate.  
The stability of some conjugates under the conditions used for the biological tests, as well as 
the metabolism in lysosomal homogenates were also studied. Interestingly, conjugate 3 
containing the parent homing peptide decomposed faster in serum than conjugate 13 in which 
the Gly was replaced by Phe. In this way, not only the anti-tumour effect, but also the stability 
of the conjugates was also improved. The difference in the stability of the conjugates might 
have some influence both on the in vitro and in vivo studies. Because in all conjugates the 
Dau was linked to the same spacer sequence, the released metabolite in lysosomal 
homogenate was identical and the speed of its release was not significantly influenced by the 
sequence of the homing peptide. Altogether, we can conclude that the observed in vitro anti-
tumour activity depends on the cellular uptake and the stability of the conjugates.  
To measure the selectivity of the conjugates for HT-29 colon cancer cells, the anti-tumour 
activity of conjugate 3 with the parent homing peptide and conjugate 13 (G/F) were measured 
on 22 different cancer cell lines and on MRC-5 human fibroblast cells. To our surprise, both 
conjugates showed one of the highest IC50 values on HT-29 cells. Therefore, we can draw a 
conclusion, that the targeting moiety is not selective to HT-29 colon cancer cells. 
Nevertheless, conjugate 13 was more effective (1.2–5 times) than conjugate 3 on all cell lines. 
The lowest effect of the conjugates was observed on fibroblast cells, suggesting selectivity of 
the conjugates to tumour cells.  
During the selection of the VHLGYAT heptapeptide by phage display, Zhang et al. did not 
identify the receptor on HT-29 cancer cells [13]. The selectivity of the peptide was not 
checked on a broad spectrum of tumour types either. Interestingly, our measurements on 
different types of cancer cell lines did not show selectivity to HT-29 cells. Therefore, we 
searched sequence homology in the literature. In the manuscript published by Fourie et al., we 
found two peptides A6R (ASHLGLAR) and HbS (VHLTPVEK) that have overlapping 
sequence with our parent peptide (see in bold) [23]. Both of them bind to Hsp70 but the de 
novo A6R peptide has higher affinity. HbS peptide is originated from the N-terminus of 
hemoglobin B chain [24] and it was also indicated that hemoglobin interacts with cytosolic 
Hsp70 efficiently [25]. In our experiments, the replacement of Gly to Thr and Ala to Leu 
increases the biological effect, furthermore, these changes also enhance the similarity of the 
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sequence with Hbs peptide. According to the literature, heat shock protein 70 (Hsp70) is 
overexpressed in a large variety of different tumour types and it is localized not only 
intracellularly, but also tumour selective Hsp70 expression in the plasma membrane was 
determined [26]. A membrane Hsp70 positive tumour phenotype is associated with 
aggressiveness and therapy resistance of cancer and the membrane-bound Hsp70 plays a 
pivotal role in eliciting anti-tumour immune response. Furthermore, it can be a good target for 
targeted tumour therapy. All of these make a strong suggestion that VHLGYAT based 
homing peptides might be recognized by membrane-bound Hsp70, though further studies are 
in progress to confirm this assumption.  
The in vivo tumour growth inhibition was measured on orthotopically developed HT-29 colon 
cancer bearing mice. The results indicate that conjugate 13 has better anti-tumour effect than 
conjugate 3 with the parent homing peptide. This effect was similar to the activity of the free 
Dau used in maximal tolerated dose, however, much lower liver toxicity was observed in the 
groups treated with the conjugates. In addition to the other positive quality of conjugate 13, 
much lower proliferation index was obtained in tumours in the group treated with conjugate 
13 than in groups treated with conjugate 3 that resulted in significantly higher tumour growth 
inhibition.  
In conclusion, it is worth to modify tumour homing peptides selected by phage display 
technique for the development of small molecule drug conjugates with increased bioactivity 
and stability that can be applied efficiently for targeted tumour therapy. In addition, the 
selectivity of the conjugates has to be determined. In our case, it seems that the homing 
peptide selected by phage display has affinity to a broad spectrum of different tumour cells 
that might be related to the cell surface protein Hsp70 as possible target. 
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